PT: Personalized Treatment for Eating Disorders Versus CBT-E Trial

Sponsor
University of Louisville (Other)
Overall Status
Recruiting
CT.gov ID
NCT05195840
Collaborator
National Institute of Mental Health (NIMH) (NIH)
80
1
2
31.8
2.5

Study Details

Study Description

Brief Summary

The scientific premise, developed from past work, is that treatment personalized based on idiographic models (termed Network Informed Personalized Treatment; NA-PT) will outperform the current gold-standard treatment (Enhanced Cognitive Behavioral Therapy: CBT-E). The study goals are to (1) develop and test the acceptability, feasibility, and preliminary efficacy of a randomization of NA-PT versus CBT-E and (2) to test if network-identified precision targets are the mechanism of change. These goals will ultimately lead to the very first personalized treatment for ED and can be extended to additional psychiatric illnesses. Specific aims are (1) To collect preliminary data on the feasibility and acceptability of the randomization of NA-PT (n=40) for EDs versus CBT-E (n=40), (2) To test the initial clinical efficacy of NA-PT versus CBT-E on clinical outcomes (e.g., ED symptoms, body mass index, quality of life) and (3) To examine if changes in NA-identified, precision targets, as well as in dynamic network structure, are associated with change in clinical outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Personalized Treatment for Eating Disorders
  • Behavioral: Cognitive Behavioral Therapy for Eating Disorders
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Pilot Investigation of Network-Informed Personalized Treatment for Eating Disorders Versus Enhanced Cognitive Behavioral Therapy and Dynamic Mechanisms of Change
Actual Study Start Date :
Apr 6, 2022
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalized Treatment for Eating Disorders

Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of personalized treatment for eating disorders.

Behavioral: Personalized Treatment for Eating Disorders
The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.

Active Comparator: Cognitive Behavioral Therapy for Eating Disorders

Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of Cognitive Behavioral Therapy for Eating Disorders.

Behavioral: Cognitive Behavioral Therapy for Eating Disorders
The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.

Outcome Measures

Primary Outcome Measures

  1. Change in Clinical Impairment using the Clinical Impairment Assessment [Up to 1-Month Follow-Up]

    The Clinical Impairment Assessment (CIA), a self report measure, is assessed at multiple time points throughout the duration of the study and is used to examine the severity of psychosocial impairment caused by eating disorders. The scores range from 0 to 64 with higher scores indicating more impairment.

  2. Change in Eating Disorder Symptoms using the Eating Disorder Examination Questionnaire [Up to 1-Month Follow-Up]

    The Eating Disorder Examination Questionnaire (EDE-Q), a self report measure, is assessed at multiple time points throughout the duration of the study and is used to examine attitudes and behaviors in individuals with eating disorder symptoms. The scores range from 0-6 with higher scores indicating higher severity of eating disorder symptoms.

  3. Change in Quality of Life using the Quality of Life Scale [Up to 1-Month Follow-Up]

    The Quality of Life Scale (QOLS), a self report measure, is assessed at multiple time points throughout the duration of the study and is used to examine various domains of quality of life. Scores range from 16 to 112 with higher scores indicating better quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18-65

  • Meets criteria for DSM-5 defined AN, BN, BED, or OSFED (Atypical AN and Atypical BN)

  • Not currently receiving psychological treatment focused on ED

Exclusion Criteria:
  • Under 18

  • Over 65

  • Does not meet criteria for DSM-5 defined AN, BN, BED, or OSFED (Atypical AN and Atypical BN)

  • High and active Suicidality

  • Active Mania

  • Medically Compromised Status including extremely low weight - less than or equal to 75% median BMI for age, sex, and height

  • Simultaneous psychological treatment focused on ED

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eating Anxiety Treatment Laboratory and Clinic Louisville Kentucky United States 40205-1016

Sponsors and Collaborators

  • University of Louisville
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Cheri A Levinson, PhD, University of Louisville

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Cheri Levinson, Associate Professor, University of Louisville
ClinicalTrials.gov Identifier:
NCT05195840
Other Study ID Numbers:
  • IRB#: 21.0689
  • 1R34MH128213-01
First Posted:
Jan 19, 2022
Last Update Posted:
Apr 15, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cheri Levinson, Associate Professor, University of Louisville
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2022